Sugarloaf Wealth Management LLC Purchases 175 Shares of Chemed Co. (NYSE:CHE)

Sugarloaf Wealth Management LLC raised its stake in Chemed Co. (NYSE:CHE) by 3.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,865 shares of the company’s stock after purchasing an additional 175 shares during the period. Chemed makes up approximately 0.7% of Sugarloaf Wealth Management LLC’s holdings, making the stock its 28th biggest position. Sugarloaf Wealth Management LLC’s holdings in Chemed were worth $3,525,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CHE. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Chemed during the 1st quarter worth about $1,064,000. ProShare Advisors LLC grew its position in shares of Chemed by 6,288.9% during the 1st quarter. ProShare Advisors LLC now owns 50,600 shares of the company’s stock worth $32,482,000 after buying an additional 49,808 shares during the period. Cim LLC acquired a new stake in shares of Chemed during the 4th quarter worth approximately $1,328,000. Sei Investments Co. boosted its position in shares of Chemed by 4.5% during the first quarter. Sei Investments Co. now owns 41,336 shares of the company’s stock worth $26,535,000 after purchasing an additional 1,780 shares in the last quarter. Finally, American National Bank & Trust Co. VA acquired a new position in Chemed in the first quarter valued at about $3,122,000. 95.85% of the stock is owned by institutional investors.

Chemed Stock Performance

NYSE CHE traded up $4.74 during trading hours on Tuesday, reaching $582.51. 9,069 shares of the company’s stock were exchanged, compared to its average volume of 83,441. The company’s 50-day moving average is $579.68 and its two-hundred day moving average is $573.00. Chemed Co. has a one year low of $497.36 and a one year high of $654.62. The company has a market capitalization of $8.82 billion, a price-to-earnings ratio of 31.23, a price-to-earnings-growth ratio of 2.40 and a beta of 0.44.

Chemed (NYSE:CHE) last released its earnings results on Wednesday, July 24th. The company reported $5.47 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.59 by ($0.12). The firm had revenue of $595.88 million for the quarter, compared to the consensus estimate of $599.20 million. Chemed had a return on equity of 29.21% and a net margin of 12.88%. Chemed’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter last year, the company posted $4.71 EPS. Research analysts predict that Chemed Co. will post 21.77 earnings per share for the current fiscal year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 12th were issued a $0.50 dividend. This is a boost from Chemed’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend was Monday, August 12th. This represents a $2.00 annualized dividend and a dividend yield of 0.34%. Chemed’s dividend payout ratio (DPR) is presently 10.76%.

Insider Activity

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $569.63, for a total value of $1,139,260.00. Following the completion of the transaction, the chief executive officer now owns 105,735 shares in the company, valued at $60,229,828.05. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Chemed news, Director George J. Walsh III sold 200 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $577.95, for a total transaction of $115,590.00. Following the completion of the sale, the director now directly owns 3,446 shares in the company, valued at $1,991,615.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the sale, the chief executive officer now owns 105,735 shares of the company’s stock, valued at $60,229,828.05. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,144 shares of company stock worth $5,264,839 in the last quarter. Corporate insiders own 3.32% of the company’s stock.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.